Rexahn Pharmaceuticals Granted European Patent for Anti-cancer Compound RX-3117
Rexahn Pharmaceuticals, Inc. announced that the European Patent Office has granted a patent for its novel anti-cancer compound, RX-3117.
"In addition to our co-development partnership with Teva, this European patent award further validates the commercial potential of RX-3117," said Dr. Chang Ahn, Rexahn's Chairman and Chief Executive Officer. "The development of RX-3117 strengthens our oncology pipeline, which includes ArchexinTM, currently in Phase II clinical trials."
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. Potential indications of RX-3117 are solid tumors including colon, lung and pancreatic cancers. In preclinical trials, RX-3117 has demonstrated its ability to overcome cancer drug resistance in cancer cells, in particular, gemcitabine-resistance in the human lung cancer cell. The US patent issued for RX-3117 claims composition of matter, synthesis, and methods (2008).
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.